TickerTalks
Browse all tickers →
TickerTalks›$BTSG
BTBTSG

BrightSpring Health Services, Inc. Common Stock

$BTSG·$11B·Medical - Healthcare Information Services·Healthcare
$56.58+1.0%YTD+49.3%1Y+105.7%
Price updated 2m ago·X counts updated 12d ago
BTBTSG
$BTSGBrightSpring Health Services, Inc. Common Stock
$56.58+1.00%36 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $BTSG on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

36X posts · last 7 days
Sep 7Sep 13
Bullish sentimentAI analysisGenerated by AI from underlying data6 posts analyzed · as of 2026-08-07

BrightSpring Health Q2 delivered 23% YoY revenue growth to $3.87B and a 44% surge in adjusted EBITDA — a strong beat-and-raise driven by specialty-pharmacy mix and acquisitions. The Community Living divestiture completed. Posters read strong specialty-generics trends across the industry as bullish for TOI as well. Some see the Friday reaction as an over-reaction to a solid print. BTSG is called a great ultimate buyer of TOI if a deal eventually happens.

Read what X is saying about $BTSG

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $BTSG — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Driven by hypeAcceleratingAI verdict · as of 2026-09-24

The move is getting stronger, with heavier trading behind it.

BrightSpring Health delivered 23% Q2 revenue growth and 44% adjusted EBITDA surge on specialty-pharmacy mix — a mid-cap healthcare-services franchise up 99% over the year.

BTSG is a mid-cap specialty-pharmacy and home-health franchise executing above-plan operational metrics — Q1 revenue $3.61B grew 25.6% YoY, EPS $0.73 with 3.8% operating margin, four consecutive positive EPS beats (+13.6%, +34.5%, -2.9%, +13.9%).

  • Q2 specifics: revenue $3.87B (+23% YoY), adjusted EBITDA +44% surge on specialty-pharmacy mix, Community Living divestiture completed.
  • Fundamentals reflect scale-and-margin build: PE 49.9, PS 0.82 (deep discount to revenue), EV/EBITDA 20.6, ROE 12.7%, gross margin 12% (specialty-pharmacy typical), D/E 1.36, FCF yield 3.7%.
  • Sept 17 concern: $200M IRA hit but efficiency may protect profitability — the specific pushback narrative.
  • Consensus 2026 EPS $1.82 puts forward PE ~30.6× — full for the growth trajectory.
  • Structural: position 64% of 52-week range, volume multiplier 0.81, beta 1.85.
  • Insider tape: Greenwell M-Exempt + Sale $874K — modest.
  • Chatter (6 posts) is bullish — Q2 beat-and-raise from specialty-pharmacy mix + acquisitions, TOI ultimate buyer thesis, some see Friday reaction as over-reaction to solid print.

Oct 29 Q3 print at $0.46 EPS is the setup — a fifth consecutive beat with specialty-pharmacy segment growth commentary and IRA impact quantification are the multi-quarter thesis tells.

Agrees with X sentimentX captures the Q2 beat-and-raise accurately — 23% YoY revenue growth to $3.87B, 44% adj EBITDA surge, specialty-pharmacy mix as driver, and Community Living divestiture completed are all documented fundamentals. TOI ultimate-buyer thesis adds M&A optionality. Bullish framing is well-evidenced.

What to watch: Oct 29 Q3 print at $0.46 EPS — a fifth consecutive beat with specialty-pharmacy segment growth commentary, IRA hit quantification and offsetting efficiency measures, and Provider Services segment execution are the multi-quarter thesis tells. Watch peer prints from AMN Healthcare and Owens & Minor for the healthcare-services sector demand context.

On the calendar: 2026-10-29

Read the AI verdict on $BTSG

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Delivers home and community-based pharmacy and clinical care services to Medicare and Medicaid populations across the U.S.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Information Services sits in its cycle right now — and what that implies for $BTSG.

Medical - Healthcare Information Services · Healthcare

AI-driven clinical workflow digitization and prior-authorization automation are the structural demand drivers; Tempus/Merck AI genomics partnership validates the platform-data model for pharma co-investment. Sector +22% T12M reflects durable AI-workflow thesis; Doximity class action is a company-specific risk.

What this means for $BTSG

Neutral — BrightSpring delivers home-based pharmacy and clinical care to Medicare/Medicaid populations; healthcare information technology is not the primary driver; reimbursement rates and care utilization are the dominant variables.

Industry benchmark

10-name peer basket
+12.5%YTD
+2.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
49.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
7.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
3.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
12.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
12.2%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 31, 2026$0.45$0.40+13.6%
Q1 2026May 1, 2026$0.39$0.29+34.5%
Q4 2025Feb 27, 2026$0.33$0.34-2.9%
Q3 2025Oct 31, 2025$0.30$0.26+13.9%
Next earningsThu, Oct 29·consensus EPS $0.46

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$3.6B+25.6%13.3%3.8%$0.73$101.4M
Q4 FY25$3.6B+16.3%11.6%4.0%$0.38$193.9M
Q3 FY25$3.3B+14.7%11.8%3.2%$0.27$92.2M
Q2 FY25$3.1B+29.1%11.9%2.6%$0.14$24.7M

Forward consensus

5-year forecast · up to 14 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$15.3B$15.1B – $15.5B$1.82$1.70 – $1.9513
FY27$17.4B$17.2B – $17.6B$2.31$2.12 – $2.4914
FY28$19.9B$18.8B – $21.8B$2.81$2.24 – $3.3813
FY29$24.5B$23.9B – $25.5B$3.82$3.70 – $4.0211
FY30$30.9B$30.2B – $32.2B$5.45$5.29 – $5.746

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.63%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-9.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+8.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 150.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.855-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 14Scott A. GreenwellPresident15.1K sh$874KSellJun 5Jennifer A PhippsCFO35.0K sh$2.1MSellJun 5Kkr Phoenix Aggregator L.p.10% owner14.7M sh$857.5MSellJun 5Lisa A NalleySee Remarks35.0K sh$2.1MSellJun 5Jon B RousseauSee Remarks260.0K sh$15.3MSellJun 5Kkr Group Partnership L.p.10% owner14.7M sh$857.5M
+ 16 other (4 exempts · 4 inkinds · 4 awards · 2 gifts · 2 others) in window

See when $BTSG insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJun 123
AI summary

Form 3 filed by Nigam H. Shah on June 12, 2026 reporting initial beneficial ownership in BrightSpring Health Services, Inc. as of his June 11, 2026 board appointment date. Shah reports no securities currently beneficially owned. Administrative insider-reporting filing — confirms Section 16 reporting status for a newly appointed director with no share position disclosed at this time.

8-KOfficer or director changeJun 128-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

BrightSpring Health Services, Inc. appointed Dr. Nigam H. Shah to its Board of Directors on June 11, 2026 as a Class III director, expanding the board from 7 to 8 members; Dr. Shah will also join the Quality and Compliance Committee and receive standard non-employee director compensation. Dr. Shah's background in healthcare AI and data science at Stanford adds specialized technical expertise to a home and community-based health services company navigating complex care coordination workflows.

SC 13D/AActivist amendmentJun 5SC 13D/A
AI summary

With filed Amendment No. 5 to Schedule 13D disclosing updated beneficial ownership in BTSG (BTSG). The filing covers approximately 26,829,880 shares of BTSG. The position is held for potential M&A activity. Schedule 13D amendments are required when a 5%-or-greater holder's ownership, intent, or plans change materially, providing transparency into concentrated positions that could influence corporate governance or trigger M&A activity.

8-KMaterial agreementJun 58-K — Item 1.01: Material agreement
AI summary

BrightSpring Health Services, Inc. (BTSG) disclosed a material definitive agreement under Item 1.01, reporting a merger or acquisition transaction involving growth company as defined in Rule. The deal is valued at approximately $0. Details of the transaction terms, consideration structure, and closing conditions are set forth in the full 8-K filing. Definitive merger agreements are among the most material events a public company can disclose, triggering regulatory review and shareholder vote requirements.

8-KShareholder voteMay 218-K — Item 5.07: Shareholder vote
AI summary

BrightSpring Health Services, Inc. (BTSG) filed an 8-K on May 21, 2026 disclosing annual shareholder meeting vote results (Item 5.07). BrightSpring is a Louisville, Kentucky-based healthcare services company providing pharmacy and home health services, listed on Nasdaq. Annual meeting results are routine administrative governance disclosures.

8-KAcquisition completedMar 318-K — Item 2.01: Acquisition completed · Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

BTSG disclosed a personnel change (8-K Item 5.02, dated 2026-03-31). An executive departure and a new appointment are both reported. President, ResCare Community Living. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

+ 12 other (5 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Best Momentum Stocks to Buy for September 24thzacks.com·1d ago3 Momentum Anomaly Stocks to Buy as Markets Surge on AI Rallyzacks.com·3d agoBTSG Faces $200M IRA Hit but Efficiency May Protect Profitabilityzacks.com·8d agoBrightSpring Health Services, Inc. (BTSG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com·10d agoHere's Why You Should Add BrightSpring Stock to Your Portfolio Nowzacks.com·10d ago

More in Medical - Healthcare Information Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TEM$SOPH$HNGE$DOCS$HTFL$TDOC$HCAT$OPRX
Voices on X · last 7 days

No standout posts about $BTSG on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport